Di Yang

Di Yang

Auto-generated profile, based on publicly available information

Di Yang

Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Chemical Engineering Journal
Verified
Journal Article
Closed access
CSChao Sun
Chao Sun
YWYuan Wang
Yuan Wang
QTQingshuang Tang
Qingshuang Tang
DYDi Yang
Di Yang
LHLu Hou
Lu Hou
YWYong Wang
Yong Wang

2 June 2025 in eLife
Verified
Journal Article
Open access
XGXuantong Gong
Xuantong Gong
LGLishuang Gu
Lishuang Gu
DYDi Yang
Di Yang
YHYu He
Yu He
QLQian Li
Qian Li
YWYong Wang
Yong Wang
Triple-negative breast cancer (TNBC), an aggressive malignancy with limited tools to predict recurrence and drug sensitivity, exhibits ferroptotic heterogeneity across subtypes. However, the tumor microenvironment (TME) mediated by ferroptosis-related genes remains poorly characterized. This study integrates single-cell and bulk RNA sequencing data from the Gene Expression Omnibus to elucidate ferroptosis-driven TME features in TNBC, employing machine learning to develop prognostic and therapeutic response prediction models. At the single-cell level, T cells were classified into three subpopulations and macrophages into two subpopulations, with their infiltration degrees significantly correlated with clinical outcomes. A risk score model constructed based on these findings demonstrated robust predictive performance, validated in external cohorts with 3-, 4-, and 5-year area under the receiver operating characteristic curves of 0.65, 0.67, and 0.71, respectively. Notably, high-risk patients exhibited enhanced sensitivity to 27 therapeutic agents. By delineating ferroptosis-associated immune heterogeneity, this work provides a risk stratification tool to enhance prognostic precision and therapeutic decision-making in TNBC, while identifying genes offer actionable targets for TNBC precision medicine.